Eteplirsen Use in a Boy with Duchenne Muscular Dystrophy and Sickle Cell Anemia

Case Rep Neurol. 2022 Oct 24;14(3):404-407. doi: 10.1159/000527358. eCollection 2022 Sep-Dec.

Abstract

Eteplirsen is an antisense oligonucleotide used in the treatment of Duchenne muscular dystrophy (DMD). The safety of eteplirsen use in individuals with rare comorbid conditions is not known. We present the case of a 4-year-old boy with a DMD exon deletion amenable to treatment with eteplirsen and comorbid sickle cell anemia. He has received eteplirsen treatment for 3 years with no clear adverse effects, including no increase in sickle cell crises.

Keywords: Children; Duchenne muscular dystrophy; Mutation; Treatment.

Publication types

  • Case Reports

Grants and funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.